Trends in Patient Access to and Utilization of Prescribed PCSK9 Inhibitors in a Large US Claims Database From 2015 to 2021
Correspondence to: Diane E. MacDougall, MS, Family Heart Foundation, 5548 First Coast Hwy, Suite 204, Fernandina Beach, FL 32034. Email Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death in the United States. LDL-C (low-density lipoprotein cholesterol) is a key driver and modifiable risk factor of ASCVD, particularly in high-risk patients, including those with genetic lipid disorders. 1 PCSK9i (proprotein convertase subtilisin/kexin type 9) inhibitors represented a maj or